867326-45-2

Upstream product

• 867326-43-0 (2S,3R)-3-(3-phenethylamino-propyl)-1-((S)-1-phenyl-ethyl)pyrrolidine-2-carboxylic acid ethyl ester 
• 867326-41-8 C₁₈H₂₅NO₃ 
• 867326-39-4 (2S,3R)-3-but-3-enyl-1-((S)-1-phenyl-ethyl)pyrrolidine-2-carboxylic acid ethyl ester 
• 186586-65-2 [but-3-enyl-((S)-1-phenyl-ethyl)amino]acetic acid ethyl ester 
• 114963-47-2 N-(3-butenyl)-N-[(S)-1-phenylethyl]amine 
• 2627-86-3 (S)-1-phenyl-ethylamine 

Downstream Products

• 867326-49-6 (3aR,8aS)-7-phenethyl-decahydro-pyrrolo[2,3-c]azepine 
• 1196042-65-5 C₂₄H₃₇N₃O 

Relevant academic research and scientific papers

Immunomodulation by IAP inhibitors

The present invention is directed to immune adjuvants containing IAP inhibitors, including Smac mimetics. The invention further provides pharmaceutical compositions and vaccines containing an IAP inhibitor and an antigen. Methods of enhancing an immune re

NOL3 IS A PREDICTOR OF PATIENT OUTCOME

The present invention features a method for determining the prognosis for survival of a cancer patient. Methods for measuring the level of NOL3 expression in a cancer cell-containing sample from a patient, and comparing the level of NOL3 expression in the

Organic compounds

Novel compounds that inhibit the binding of the Smac protein to Inhibitor of Apoptosis Proteins (IAPs) of the formula I